Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stage C

Next Previous
Trial Profile

A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stage C

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Istaroxime (Primary) ; Vasopressors
  • Indications Cardiogenic shock; Decompensated heart failure
  • Focus Therapeutic Use
  • Acronyms SEISMiC-C
  • Sponsors Windtree Therapeutics

Most Recent Events

  • 30 Jun 2025 According to a Windtree Therapeutics media release, Company has reached the planned enrollment of 20 patients for the interim analysis in its istaroxime Phase 2 SEISMiC C study in SCAI Stage C cardiogenic shock patients.
  • 06 May 2025 According to a Windtree Therapeutics media release, Interim analysis of this trial is planned in Q3, 2025.
  • 30 Oct 2024 According to a Windtree Therapeutics media release, this SCAI Stage C trial is important for Phase 3 readiness of istaroxime in cardiogenic shock because these patients are intended to be part of the target patient population. The data from this trial will also be useful for discussions with regulatory agencies, planned in 2025 to finalize plans for the Phase 3 program design.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top